Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
The authors propose "decreased-dose-intensity" PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.
Ty
A U
AU
Department of Neurology, National Neuroscience Institute, Singapore General Hospital Campus, Singapore.
See
S J
SJ
Rao
J P
JP
Khoo
J B K
JB
Wong
M C
MC
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D044466:Asian People; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000208:ethnology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000208:ethnology*; D011344:Procarbazine / Q000008:administration & dosage; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine